Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Rapidemic

Financiado

Rapidemic – A lysis buffer for a novel molecular point-of-care diagnostic device...

Rapidemic – A lysis buffer for a novel molecular point-of-care diagnostic device for sexually transmitted infections Sexually transmitted infections (STI) are some of the most prevalent endemic infections in Europe. Current diagnostic techniques for STI’s have important shortcomings, as they rely on central diagnostic laboratories with extensive... ver más

31/12/2023

RAPIDEMIC B.V.

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

RAPIDEMIC B.V. No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-31

HORIZON-EIE-2022-SCALEUP-02-02: Women TechEU ExpectedOutcome:Project results are expected to contribute to the following expected outcomes:

Innovación

Cerrada hace 2 años

0% 100% 100%

1 Participantes

RAPIDEMIC B.V.

75.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PTQ2020-011388 Implementación y validación de la tecnología DGL-TechTM a tr... 21K€ Cerrado

PID2020-118904RB-C22 DESARROLLO DE TESTS RAPIDOS Y ULTRASENSIBLES PARA INFECCIONE... 74K€ Cerrado

RAPP-ID Development of RApid Point-of-Care test Platforms for Infect... 16M€ Cerrado

PID2020-116770RJ-I00 DETECCION DE MALARIA GRAVE USANDO UN NUEVO TEST DE DIAGNOSTI... 182K€ Cerrado

DUALSAVE-FGS Dual screening by Spectral Artificial Visual Examination (SA... 8M€ Cerrado

HistPhilMedTest Is This A Good Medical Test? 190K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2023-06-02
Fecha Fin: 2023-12-31

Líder del proyecto

RAPIDEMIC B.V. No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 75K€

Descripción del proyecto Sexually transmitted infections (STI) are some of the most prevalent endemic infections in Europe. Current diagnostic techniques for STI’s have important shortcomings, as they rely on central diagnostic laboratories with extensive high-throughput facilities with expensive equipment and trained personnel. Due to this, the turnover of patient samples can take up to a week. In the meantime, patients are experiencing shame and pain. This delay in diagnosis can also have more important consequences, such as continued spread of the infections, of the development of pelvic inflammatory disease, which can lead to infertility. This is why Rapidemic develops an innovative molecular point-of-care diagnostic device for fast and accurate diagnosis of chlamydia and gonorroea. With this test, patient samples no longer have to travel to a lab, but patients can immediately get tested at a sexual health clinic. This single-visit testing provides an opportunity for immediate treatment administration and to drastically reduce the patients discomfort, therby decreasing the barrier to test. To detect a pathogen’s DNA in the Rapidemic test, the bacteria first have to release the DNA. In this project, Rapidemic will be working on the research and development of a novel lysis buffer for gram negative bacteria, suitable for integration in a molecular point-of-care diagnostic device.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores